Transdermal therapeutic system and method of use thereof for treating parkinsonism
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/70
A61K-031/381
출원번호
US-0931762
(2007-10-31)
등록번호
US-10251844
(2019-04-09)
우선권정보
DE-198 14 084 (1998-03-30)
발명자
/ 주소
Müller, Walter
Peck, James V.
출원인 / 주소
LTS LOHMANN THERAPIE-SYSTEME AG
대리인 / 주소
Harness, Dickey and Pierce, P.L.C.
인용정보
피인용 횟수 :
0인용 특허 :
66
초록▼
A substantially solvent-free matrix layer containing (−)-5,6,7,8-tetrahydro-6-propyl-2-(2-thienyl)ethylamino-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the s
A substantially solvent-free matrix layer containing (−)-5,6,7,8-tetrahydro-6-propyl-2-(2-thienyl)ethylamino-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.
대표청구항▼
1. A transdermal therapeutic system (TTS) comprising a self-adhesive matrix that comprises an acrylate-based or silicone-based polymer adhesive system having distributed therein (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by we
1. A transdermal therapeutic system (TTS) comprising a self-adhesive matrix that comprises an acrylate-based or silicone-based polymer adhesive system having distributed therein (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight of the matrix. 2. The TTS of claim 1, wherein the matrix is substantially solvent-free. 3. The TTS of claim 1, wherein the adhesive system is acrylate-based, comprising a polymer containing at least two types of monomer selected from the group consisting of acrylic acid, acrylamide, hexylacrylate, 2-ethylhexylacrylate, hydroxyethylacrylate, octylacrylate, butylacrylate, methyl-acrylate, glycidylacrylate, methacrylic acid, methacrylamide, hexylmethacrylate, 2-ethylhexylmethacrylate, octylmethacrylate, methylmethacrylate, glycidyl-methacrylate, vinylacetate and vinylpyrrolidone, at least one of said types being an acrylic or methacrylic acid derivative. 4. The TTS of claim 1, said TTS being of sufficient size, when applied to skin of a subject, to administer a daily dose of the free base and to achieve thereby a therapeutic level of the free base. 5. The TTS of claim 4, wherein the size of the TTS is 2 to 40 cm2. 6. The TTS of claim 4, wherein the size of the TTS is approximately 20 cm2. 7. The TTS of claim 1, wherein the free base is present in the matrix in an amount that makes available for transdermal delivery a 1-10 mg dose of the free base. 8. The TTS of claim 1, wherein the matrix layer has a coat weight of approximately 50 g/m2. 9. The TTS of claim 1, wherein the free base is present in the matrix layer in an amount of approximately 0.45 mg/cm2. 10. The TTS of claim 1, wherein the adhesive system is silicone-based, comprising (a) an amine-resistant polydimethylsiloxane adhesive wherein methyl groups are optionally replaced by ethyl or phenyl groups, and (b) an additive having increased solubility for the free base, in an amount effective to increase dissolving capacity of the matrix for the free base. 11. The TTS of claim 1, wherein the free base is present in an amount of about 5% to 25% by weight. 12. The TTS of claim 1, wherein the free base is present in an amount of about 5% to about 15% by weight. 13. The TTS of claim 1, wherein the free base is present in an amount of approximately 9% by weight. 14. The TTS of claim 1, wherein the silicone adhesive is amine-resistant. 15. The TTS of claim 1, wherein the silicone-based adhesive system comprises BIO-PSA Q7-4301 or BIO-PSA Q7-4201. 16. The TTS of claim 10, wherein the additive comprises polyvinylpyrrolidone, a copolymer of vinylpyrrolidone and vinyl acetate, polyethylene glycol, polypropylene glycol, glycerol, a fatty acid ester of glycerol and/or a copolymer of ethylene and vinyl acetate. 17. The TTS of claim 10, wherein the additive comprises polyvinylpyrrolidone in an amount of about 1.5-5% by weight of the matrix. 18. The TTS of claim 17, wherein the polyvinylpyrrolidone is present in an amount of about 1.5% to 3% by weight of the matrix. 19. The TTS of claim 17, wherein the polyvinylpyrrolidone is of type 90F.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (66)
Jaeger Halvor (Neu-Ulm DEX) Hoffmann Hans-Rainer (Neuwied DEX) Meconi Reinhold (Neuwied DEX) Klein Robert-Peter (Neuwied DEX), Apparatus for the delivery of substances, processes for the production thereof and use thereof.
Thomas E. Conn ; Russell Ford ; Pravin L. Soni ; Michael J. Tierney ; Prema Vijayakumar, Collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems.
Gueret Jean-Louis H.,FRX, Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbi.
Michael J. Butler ; Thomas E. Conn ; David M. Liu ; Norman A. Parris ; Michael Reidy ; Pravin L. Soni, Device and methods for the application of mechanical force to a gel/sensor assembly.
Cody Wayne L. (Saline MI) DePue Patricia (Canton MI) Doherty Annette M. (Ann Arbor MI) He John X. (Ypsilanti MI) Taylor Michael D. (Ann Arbor MI), Endotherlin antagonists.
Wong Ooi (Fremont CA) Nguyen Thuytien N. (Hayward CA), Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters.
Hoffmann Hans-Rainer (Neuwied DEX) Klein Robert P. (Neuwied DEX) Meconi Reinhold (Neuwied DEX) Cordes Gunter (Leichingen DEX) Wolff Hans M. (Monheim DEX), Estrogen-containing active substance plaster.
Roreger Michael (Neuwied DEX) Herrmann Fritz (Neuwied DEX) Hoffmann Hans-Rainer (Neuwied DEX) List Harald (Neuwied DEX), Flexible, hydrophilic gel film, the process for its production and the use of it.
Rimpler,Stephan; Grapatin,Sabine; Krein,Cliff; Thelen,Markus, Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients.
Roos Eric J. (Marlborough MA) Chiang Chia-Ming (Foster City CA) Hsu Tsung-Min (Taipei TWX), Low flux matrix system for delivering potent drugs transdermally.
Colley Kenneth J. (San Francisco CA) Wilson Donald R. (San Francisco CA) Cleary Gary W. (San Mateo CA) Lammintausta Risto (Turku FIX) Jalonen Harry (Turku FIX), Method and device for administering dexmedetomidine transdermally.
Maignan Jean (Tremblay les Gonesse FRX) Malle Grard (Villiers sur Morin FRX) Deflandre Andr (Orry-La-Ville FRX) Lang Grard (Saint Gratien FRX), New derivatives of 5,6,7,8-tetrahydro-1-naphthalenol, a process for their preparation and cosmetic and pharmaceutical co.
Wolter Karin (Melsbach DEX) Mller Walter (Neuwied DEX) Simon Gnter (Hillesheim DEX) Nalbach Christa (Leutesdorf DEX) Hoffmann Hans-Rainer (Neuwied DEX), Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a pr.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Bouwstra, Johanna Aaltje; Ackaert, Oliver; Eikelenboom, Jacob; Wolff, Hans-Michael, Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis.
Chen Tung-Fen ; Chiang Chia-Ming ; Jona Janan ; Joshi Priti ; Ramdas Asha, Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufactu.
Sylvia Rossi-Montero ; Juan Mantelle ; David Kanios ; David Houze, Solubility enhancement of drugs in transdermal drug delivery systems and methods of use.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Fallon Renee A. (Sunnyvale CA) Venkatraman Subbu S. (Palo Alto CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset.
Venktrama Subbu S. (Palo Alto CA) Fallon Renee A. (Sunnyvale CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset.
Chiang Chia-Ming (Foster City CA) Colley Kenneth J. (Washington DC) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset.
Ma Xinghang ; Audett Jay ; Soni Pravin L. ; Singh Noel ; Bailey Susan E., Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use.
Jona Janan ; Audett Jay ; Singh Noel, Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen.
Muller, Walter; Peck, James V., Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Quan Danyi ; Deshpanday Ninad A. ; Venkateshwaran Srinivasan ; Ebert Charles D., Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.